ReviewCancer prevention research (Philadelphia, Pa.)2015
Immunoprevention of human papillomavirus-associated malignancies.
Review in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion.Research square · 2024Article
- A New Generation of Vaccines in the Age of Immunotherapy.Current oncology reports · 2021Review
- Turning the corner on therapeutic cancer vaccines.NPJ vaccines · 2019Review
- Tumour virus vaccines: hepatitis B virus and human papillomavirus.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy.The Journal of general virology · 2017Article
- Cancer Prevention: Lessons Learned and Future Directions.Trends in cancer · 2016Review
- Human papillomavirus and gastrointestinal cancer: A review.World journal of gastroenterology · 2016Review
- Progress and prospects for L2-based human papillomavirus vaccines.Expert review of vaccines · 2016Review
- Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.Human vaccines & immunotherapeutics · 2016Review
- Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.Cell & bioscience · 2016Article
- Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Molecular oncology · 2015Review
- Article
- Immunologic Control of Mus musculus Papillomavirus Type 1.PLoS pathogens · 2015Article
- Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.Virology journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Persistent infection by one of 15 high-risk human papillomavirus (hrHPV) types is a necessary but not sufficient cause of 5% of all human cancers. This provides a remarkable opportunity for cancer prevention via immunization. Since Harald zur Hausen's pioneering identification of hrHPV types 16 and 18, found in approximately 50% and 20% of cervical cancers, respectively, two prophylactic HPV vaccines containing virus-like particles (VLP) of each genotype have been widely licensed. These vaccines are beginning to affect infection and HPV-associated neoplasia rates after immunization campaigns in adolescents. Here, we review recent progress and opportunities to better prevent HPV-associated cancers, including broadening immune protection to cover all hrHPV types, reducing the cost of HPV vaccines especially for developing countries that have the highest rates of cervical cancer, and immune-based treatment of established HPV infections. Screening based upon George Papanicolaou's cervical cytology testing, and more recently detection of hrHPV DNA/RNA, followed by ablative treatment of high-grade cervical intraepithelial neoplasia (CIN2/3) have substantially reduced cervical cancer rates, and we examine their interplay with immune-based modalities for the prevention and eventual elimination of cervical cancer and other HPV-related malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.